
The Medicines Company Agrees to Divest its Hemostasis Portfolio to Mallinckrodt plc

DECEMBER 21, 2015

On December 18, The Medicines Company (NASDAQ:MDCO) announced that it entered into a purchase agreement pursuant to which certain subsidiaries of Mallinckrodt plc will acquire The Medicines Company's global portfolio of three hemostasis products—RECOTHROM® Thrombin topical (Recombinant), PreveLeak™, and RAPLIXA™ (fibrin sealant)—for a total potential consideration of up to \$410 million.

The WilmerHale team representing The Medicines Company was led by Partner [Joe Conahan](#) and included Senior Associate [Michael Welhouse](#) and Associate [Mark Nysten](#) (corporate), as well as Partners [Steve Barrett](#) (IP), [Robert Burke](#) (tax), [Scott Kilgore](#) (labor and employment), [Bruce Manheim](#) (regulatory), [Hartmut Schneider](#) and Special Counsel Jeffrey Ayer (antitrust).

The formal press release can be found on www.themedicinescompany.com.